Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03953118 · ClinicalTrials.gov registry record · Phase 4
Azithromycin for Meibomian Gland Disease
A Phase 4 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT03953118 is a Phase 4 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 2 participants.
The verdict
NCT03953118, a Phase 4 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study aims to elucidate the effectiveness of oral azithromycin in treating symptomatic dry eye syndrome secondary to Meibomian gland dysfunction.
Interventions
- DRUG Placebo Oral
- DRUG Azithromycin Oral Product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-09-01 |
| Est. Completion | 2021-07-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03953118
The ClinicalTrials.gov registry entry for NCT03953118 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral is the first listed.
NCT03953118 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03953118 about?
NCT03953118 is a clinical study titled "Azithromycin for Meibomian Gland Disease". This study aims to elucidate the effectiveness of oral azithromycin in treating symptomatic dry eye syndrome secondary to Meibomian gland dysfunction.
What is the current status of trial NCT03953118?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2019-09-01. Estimated completion is 2021-07-01.
What interventions are being tested in trial NCT03953118?
The interventions under investigation include: Placebo Oral (DRUG), Azithromycin Oral Product (DRUG).
Who is sponsoring clinical trial NCT03953118?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.